Neuropathic Pain Clinical Trial
Official title:
Efficacy of Perioperative Pregabalin in Reducing the Incidence of Chronic Neuropathic Pain and Postthoracotomy Syndrome.
This study is designed to assess:
1. The impact of taking perioperative pregabalin on the incidence of chronic neuropathic
pain and postthoracotomy syndrome at 3 months in patients who have undergone a
thoracotomy with a thoracic epidural as the basic analgesic modality.
2. The impact of taking perioperative pregabalin on the relief of acute pain, and on the
use of additional analgesics, such as opioids, for the relief of such pain in patients
who have undergone thoracic surgery with a thoracic epidural as the basic analgesia.
3. The impact of taking perioperative pregabalin on the quality of life and level of
functioning of patients who underwent thoracic surgery 3 months earlier.
4. The safety profile of pregabalin in this patient population.
Hypothesis: The basic hypothesis in this study is that a dose of pregabalin administered
preemptively 1 hour before a thoracotomy, then repeatedly during the postoperative period,
when neuronal hyperexcitability is at a maximum (i.e., 4 days), will lead to a 33.3%
decrease in the prevalence of chronic pain 3 months after surgery.
Postthoracotomy pain syndrome is a rather frequent phenomenon. Its incidence, as reported in
the literature, varies but is around 52% at 1 to 2 years after surgery. This syndrome is
defined as a persistent and/or recurrent pain or burning sensation along the thoracotomy
scar at least 2 months after surgery. The pain is very significant, given that 3 to 5% of
patients report it as being severe, and approximately 50% of patients report limitations in
their activities of daily living secondary to this pain and consider their pain as their
worst medical problem. A neuropathic component makes a certain contribution to this pain.
Patients with this neuropathic component report more-severe pain and take more analgesics.
Little is known about the origin of this pain, but it seems that the intensity of acute
postoperative pain is the best predictor of it. Pregabalin could be a possible approach to
reducing the prevalence of chronic postthoracotomy pain. Its efficacy has been demonstrated
in several diabetic, postherpetic, incisional and inflammatory neuropathic pain models.
Methods:
One hundred and twenty patients will be divided in two equal groups (to receive pregabalin
or placebo).
Prior to the induction of general anesthesia, a thoracic epidural will be placed and started
immediately prior to surgery. The anesthetic technique and monitoring will be standardized.
During the immediate postoperative period, the intensity of pain will be assessed using a
VNPS (0-10). Pain will be assessed upon the patient's arrival in and discharge from the
recovery room and daily thereafter, for a total duration of four postoperative days or until
discharge from hospital if this occurs before the 4th postoperative day.
Three months after their surgery, the patients will be contacted by telephone and
administered a standardized questionnaire for evaluating:
- The presence and intensity (based on a VNPS) of pain at the surgical and/or drainage
tube sites.
- The type of pain, with specific attention to identifying the presence of neuropathic
pain.
- The patients' assessment of their quality of life, and the impact, if any, of the pain
on their level of functioning in their daily lives in relation to their preoperative
quality of life and functioning.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Completed |
NCT05235191 -
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
|
Phase 3 | |
Completed |
NCT05845177 -
Persistent Pain After Hip Replacement
|
||
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05949554 -
Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
|
||
Withdrawn |
NCT05052645 -
Ear Acupuncture for Neuropathic Pain
|
N/A | |
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Completed |
NCT02866396 -
Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
|
||
Completed |
NCT02824588 -
Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain
|
N/A | |
Active, not recruiting |
NCT02560545 -
Cannabinoids Effects on the Pain Modulation System
|
N/A | |
Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
Not yet recruiting |
NCT02246517 -
The Effect of N2O on Chronic Neuropathic Pain Patients
|
Phase 0 | |
Completed |
NCT02099890 -
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Completed |
NCT01718821 -
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
|
N/A | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Completed |
NCT01669967 -
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin
|
N/A | |
Completed |
NCT01207596 -
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
|
Phase 4 | |
Completed |
NCT01201317 -
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
|
Phase 2 |